[go: up one dir, main page]

MX2019012699A - Nanoparticulas dirigidas. - Google Patents

Nanoparticulas dirigidas.

Info

Publication number
MX2019012699A
MX2019012699A MX2019012699A MX2019012699A MX2019012699A MX 2019012699 A MX2019012699 A MX 2019012699A MX 2019012699 A MX2019012699 A MX 2019012699A MX 2019012699 A MX2019012699 A MX 2019012699A MX 2019012699 A MX2019012699 A MX 2019012699A
Authority
MX
Mexico
Prior art keywords
lipid
phospholipid
liposomes
derivatized
polymer
Prior art date
Application number
MX2019012699A
Other languages
English (en)
Inventor
Ananth Annapragada
Darren Woodside
Peter Vanderslice
Robert Market
Ronald Biediger
Richard Dixon
James T Willerson
Eric Tanifum
Original Assignee
Texas Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Childrens Hospital filed Critical Texas Childrens Hospital
Publication of MX2019012699A publication Critical patent/MX2019012699A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe aqui una composicion que comprende una pluralidad de liposomas que tienen un diametro promedio de menos de 400 nanometros, en donde la pluralidad de liposomas comprende: un primer lipido o fosfolipido; un segundo lipido o fosfolipido que se derivatiza con un polimero; y un excipiente estericamente voluminoso capaz de estabilizar los liposomas; un tercer lipido o fosfolipido derivatizado con un polímero terminado con un componente dirigido a la integrina; DSPE o un cuarto lipido o fosfolipido derivatizado con un grupo que une a un agente potenciador del contraste en donde la pluralidad de liposomas encapsula opcionalmente un componente de carga util que consiste en uno o mas agentes bioactivos.
MX2019012699A 2017-04-28 2018-04-27 Nanoparticulas dirigidas. MX2019012699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762491349P 2017-04-28 2017-04-28
PCT/US2018/029991 WO2018201069A1 (en) 2017-04-28 2018-04-27 Targeting nanoparticles

Publications (1)

Publication Number Publication Date
MX2019012699A true MX2019012699A (es) 2020-12-11

Family

ID=63919281

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012699A MX2019012699A (es) 2017-04-28 2018-04-27 Nanoparticulas dirigidas.

Country Status (12)

Country Link
US (1) US11312685B2 (es)
EP (1) EP3615087B1 (es)
JP (1) JP2020518666A (es)
KR (1) KR20200018407A (es)
CN (1) CN111093717B (es)
AU (1) AU2018258681B2 (es)
BR (1) BR112019022423A2 (es)
CA (1) CA3061174C (es)
IL (1) IL270217B2 (es)
MX (1) MX2019012699A (es)
NZ (1) NZ759001A (es)
WO (1) WO2018201069A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3860660A4 (en) * 2018-10-05 2023-01-25 Texas Heart Institute IMAGING MEDIA AND METHODS OF USE
US11614451B2 (en) * 2019-07-08 2023-03-28 Alzeca Biosciences, LLC Targeting ligands for tau pathology
JP7395759B2 (ja) * 2020-01-29 2023-12-11 テキサス チルドレンズ ホスピタル アミロイド沈着のｍｒｉのための標的造影剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62144280A (ja) 1985-12-18 1987-06-27 Tokyo Insatsu Shiki Kk メイクアツプシユミレ−タ
US6224903B1 (en) 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
PL205322B1 (pl) 1999-05-07 2010-04-30 Encysive Pharmaceuticals Inc Pochodne kwasu propionowego, środek farmaceutyczny i zastosowanie pochodnych kwasu propionowego
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US20030082103A1 (en) 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
CN101249269A (zh) * 2002-01-24 2008-08-27 巴内斯－朱威胥医院 整联蛋白靶向的影像剂
FR2856685B1 (fr) * 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
PE20070360A1 (es) * 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
US20130079383A1 (en) * 2011-07-13 2013-03-28 Arrowhead Research Corporation Lipid Compounds Targeting VLA-4

Also Published As

Publication number Publication date
JP2020518666A (ja) 2020-06-25
AU2018258681B2 (en) 2024-02-08
NZ759001A (en) 2023-03-31
CN111093717A (zh) 2020-05-01
EP3615087B1 (en) 2023-09-06
IL270217A (es) 2021-03-01
EP3615087A4 (en) 2021-03-03
CN111093717B (zh) 2023-01-31
AU2018258681A1 (en) 2019-11-07
US20210188774A1 (en) 2021-06-24
CA3061174C (en) 2024-06-04
EP3615087A1 (en) 2020-03-04
US11312685B2 (en) 2022-04-26
IL270217B2 (en) 2024-08-01
WO2018201069A1 (en) 2018-11-01
CA3061174A1 (en) 2018-11-01
BR112019022423A2 (pt) 2020-09-01
KR20200018407A (ko) 2020-02-19
IL270217B1 (en) 2024-04-01

Similar Documents

Publication Publication Date Title
SA520411636B1 (ar) صيغ جسيمات نانوية دهنية
CY1124380T1 (el) Συστηματα διαβλεννογονιας και διαδερμικης χορηγησης
MX2018006031A (es) Fibra sintetica que contiene aerogel y material de polimero, y metodos de fabricacion y articulos que comprenden los mismos.
EP3988089A4 (en) LIPID NANOPARTICLES FOR IN VIVO DRUG DELIVERY, AND ASSOCIATED USES
EP3949969A3 (en) Benzazepine compounds, conjugates, and uses thereof
MX2019012534A (es) Combinacion de elafibranor o derivados del mismo con un agente anti-ehna, antifibrotico o anticolestasico.
WO2017089890A8 (en) Conjugates comprising self-immolative groups and methods related thereto
EP4420679A3 (en) Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP4406617A3 (en) Composition for surface modification
NZ759001A (en) Targeting nanoparticles
WO2016113550A3 (en) Dressing
EP3463316A4 (en) FUNCTIONALIZED NANOPARTICLES FOR INTRACELLULAR ADMINISTRATION OF BIOLOGICALLY ACTIVE MOLECULES AND METHOD FOR THE PRODUCTION AND USE THEREOF
MX2015010083A (es) Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos.
PH12019502480A1 (en) Biological self-assembled nanocrystal injection having a lymphatic targeting function and preparation method thereof
EP3318282A4 (en) AGGREGATE COMPOSITION CARRIER AND COMPOSITION THEREOF
HK1231397A1 (zh) 包封修飾的環糊精複合物的脂質體組合物及其應用
EP4356968A3 (en) Long-acting formulations
SE1751277A1 (en) Amphiphilic antimicrobial hydrogel
MX2019007633A (es) Composicion antitranspirante /desodorante.
WO2017075171A3 (en) Pamam dendrimer based cest imaging agents and uses thereof
MX2018008868A (es) Composiciones farmaceuticas que contienen glucomanano con liberacion extendida y propiedades disuasivas de abuso.
MX393464B (es) Estructura de nucleo-envoltura, preparacion, medicina para aplicacion externa, agente de cinta y producto cosmetico.
WO2018229093A8 (en) NANOPARTICLES AS DELIVERY VEHICLES OF ACTIVE PRINCIPLES AND METHODS OF PRODUCING SAME
EP4302754A4 (en) STABLE DOCETAXEL-ALBUMIN NANOPARTICLE COMPOSITION
AU2017251957A1 (en) Hyaluronic acid conjugates and uses thereof